BLAINJECTIONINJECTABLEPriority Review
Approved
Dec 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUNSUMIO (mosunetuzumab) is a bispecific antibody approved in December 2022 for hematologic malignancies, particularly B-cell lymphomas. It bridges T cells and B cells to activate anti-tumor immunity through dual-target engagement. The mechanism leverages bispecific antibody technology to enhance cellular cytotoxicity.
Peak
Product is in peak commercial phase with moderate competitive pressure (30%), indicating active sales force and medical affairs engagement.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)
Started Jun 2026
25 enrolled
Waldenstrom Macroglobulinemia
A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Started May 2026
30 enrolled
LupusSystemic Lupus ErythematosusLupus Nephritis
Mosunetuzumab for CLL MRD Clearance
Started Nov 2025
40 enrolled
LeukemiaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma+1 more
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
Started Nov 2025
22 enrolled
Grade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular Lymphoma+2 more
A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).
Started Oct 2025
30 enrolled
Follicular Lymphoma
Worked on LUNSUMIO at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.